Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determinants of adherence in a cohort of Belgian HIV patients: a pilot study.
Degroote S, Vogelaers D, Vermeir P, Mariman A, De Rick A, Van Der Gucht B, Pelgrom J, Van Wanzeele F, Verhofstede C, Vancauwenberghe J, Vandijck D. Degroote S, et al. Among authors: van wanzeele f. Acta Clin Belg. 2014 Apr;69(2):111-5. doi: 10.1179/0001551214Z.00000000035. Acta Clin Belg. 2014. PMID: 24724750
Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy.
Verhofstede C, Noë A, Demecheleer E, De Cabooter N, Van Wanzeele F, Van Der Gucht B, Vogelaers D, Plum J. Verhofstede C, et al. Among authors: van wanzeele f, van der gucht b. J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):473-83. doi: 10.1097/00126334-200404150-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15021312
Impact of Delta 32-CCR5 heterozygosity on HIV-1 genetic evolution and variability--a study of 4 individuals infected with closely related HIV-1 strains.
Chalmet K, Van Wanzeele F, Demecheleer E, Dauwe K, Pelgrom J, Van Der Gucht B, Vogelaers D, Plum J, Stuyver L, Vandekerckhove L, Verhofstede C. Chalmet K, et al. Among authors: van wanzeele f. Virology. 2008 Sep 30;379(2):213-22. doi: 10.1016/j.virol.2008.06.036. Epub 2008 Aug 9. Virology. 2008. PMID: 18692212 Free article.
Frequency and predictors of HIV-1 co-receptor switch in treatment naive patients.
Mortier V, Dauwe K, Vancoillie L, Staelens D, Van Wanzeele F, Vogelaers D, Vandekerckhove L, Chalmet K, Verhofstede C. Mortier V, et al. Among authors: van wanzeele f. PLoS One. 2013 Nov 7;8(11):e80259. doi: 10.1371/journal.pone.0080259. eCollection 2013. PLoS One. 2013. PMID: 24244665 Free PMC article.
Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.
Libois A, Florence E, Derdelinckx I, Yombi JC, Henrard S, Uurlings F, Vandecasteele S, Allard SD, Demeester R, Van Wanzeele F, Ausselet N, De Wit S. Libois A, et al. Among authors: van wanzeele f. Acta Clin Belg. 2018 Aug;73(4):275-280. doi: 10.1080/17843286.2018.1428506. Epub 2018 Feb 12. Acta Clin Belg. 2018. PMID: 29429390
The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group.
Gisolf EH, Jurriaans S, Pelgrom J, van Wanzeele F, van der Ende ME, Brinkman K, Borst MJ, de Wolf F, Japour AJ, Danner SA. Gisolf EH, et al. Among authors: van wanzeele f, van der ende me. AIDS. 2000 Mar 10;14(4):405-13. doi: 10.1097/00002030-200003100-00014. AIDS. 2000. PMID: 10770543 Clinical Trial.
Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption.
De Scheerder MA, Van Hecke C, Zetterberg H, Fuchs D, De Langhe N, Rutsaert S, Vrancken B, Trypsteen W, Noppe Y, Van Der Gucht B, Pelgrom J, Van Wanzeele F, Palmer S, Lemey P, Gisslén M, Vandekerckhove L. De Scheerder MA, et al. Among authors: van wanzeele f. J Antimicrob Chemother. 2020 May 1;75(5):1311-1320. doi: 10.1093/jac/dkaa003. J Antimicrob Chemother. 2020. PMID: 32053203 Free PMC article.
21 results